{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:00:36Z","timestamp":1791489636693,"version":"4.3.4"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":275,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101473","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:08:22Z","timestamp":1791202102000},"page":"101473","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Rethinking cardiovascular risk stratification in TKI-treated chronic myeloid leukemia"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5502-542X","authenticated-orcid":false,"given":"Elena-Mihaela","family":"Cordeanu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanti","family":"Ame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Stephan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2026.101473_bib0001","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1001\/jama.2025.0220","article-title":"Chronic myeloid Leukemia: a review","volume":"333","author":"Jabbour","year":"2025","journal-title":"JAMA J. Am. Med. Assoc."},{"key":"10.1016\/j.ctarc.2026.101473_bib0002","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/ejh.12367","article-title":"Rapid onset of peripheral artery disease in a chronic myeloid leukemia patient without prior arterial disorder: direct relationship with nilotinib exposure and clinical outcome","volume":"94","author":"Mirault","year":"2015","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.ctarc.2026.101473_bib0003","first-page":"668","article-title":"Cardiovascular disease in patients with chronic myeloid leukemia","volume":"7","author":"Aghel","year":"2025","journal-title":"JACC: Cardiooncol."},{"key":"10.1016\/j.ctarc.2026.101473_bib0004","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/jamaoncol.2015.5932","article-title":"Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis","volume":"2","author":"Douxfils","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ctarc.2026.101473_bib0005","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s40959-025-00366-x","article-title":"The incidence of vascular adverse events and usefulness of novel risk assessment tool in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"11","author":"Watanabe","year":"2025","journal-title":"Cardio-Oncology"},{"key":"10.1016\/j.ctarc.2026.101473_bib0006","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.clml.2025.04.015","article-title":"Incidence of cardiovascular events and carotid artery USG abnormalities in chronic myeloid leukemia patients on Nilotinib therapy: a 20-year single-center study","volume":"25","author":"Jang","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.ctarc.2026.101473_bib0011","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1182\/bloodadvances.2019001329","article-title":"First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis","volume":"4","author":"Vener","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.ctarc.2026.101473_bib0007","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/ejh.13983","article-title":"Cardiovascular risk in chronic myeloid leukaemia: a multidisciplinary consensus on screening and management","volume":"111","author":"Milojkovic","year":"2023","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.ctarc.2026.101473_bib0008","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bjh.16733","article-title":"Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study","volume":"192","author":"Milojkovic","year":"2021","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ctarc.2026.101473_bib0009","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2026.101473_bib0010","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart. J."},{"key":"10.1016\/j.ctarc.2026.101473_bib0012","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00277-023-05556-0","article-title":"The new systematic coronary risk evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib","volume":"103","author":"Mulas","year":"2024","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.ctarc.2026.101473_bib0013","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/leu.2013.70","article-title":"Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib","volume":"27","author":"Kim","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.ctarc.2026.101473_bib0014","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1093\/eurheartj\/ehae179","article-title":"2024 ESC guidelines for the management of peripheral arterial and aortic diseases","volume":"45","author":"Mazzolai","year":"2024","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ctarc.2026.101473_bib0015","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1093\/eurheartj\/ehab309","article-title":"SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe","volume":"42","author":"Hageman","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ctarc.2026.101473_bib0016","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00277-015-2314-2","article-title":"Epidemiology of chronic myeloid leukaemia: an update","volume":"94","author":"H\u00f6glund","year":"2015","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.ctarc.2026.101473_bib0017","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4103\/0971-5851.123712","article-title":"Report of chronic myeloid leukemia from All India Institute of Medical Sciences, 1990-2010","volume":"34","author":"Mishra","year":"2013","journal-title":"Indian J. Med. Paediatr. Oncol."},{"key":"10.1016\/j.ctarc.2026.101473_bib0018","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s40959-024-00245-x","article-title":"Cardiovascular events in CML patients treated with Nilotinib: validation of the HFA-ICOS baseline risk score","volume":"10","author":"Fernando","year":"2024","journal-title":"Cardio-Oncology"},{"key":"10.1016\/j.ctarc.2026.101473_bib0019","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1161\/ATVBAHA.119.313353","article-title":"Tyrosine kinase inhibitors in leukemia and cardiovascular events: from mechanism to patient care","volume":"40","author":"Manouchehri","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ctarc.2026.101473_bib0020","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1016\/j.jacc.2025.11.016","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of dyslipidemia","volume":"87","author":"Blumenthal","year":"2026","journal-title":"JACC"},{"key":"10.1016\/j.ctarc.2026.101473_bib0021","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.jacc.2015.12.056","article-title":"Femoral and carotid subclinical atherosclerosis association with risk factors and coronary calcium: the AWHS study","volume":"67","author":"Laclaustra","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ctarc.2026.101473_bib0022","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jacc.2021.05.011","article-title":"Progression of early subclinical atherosclerosis (PESA) study: JACC focus seminar 7\/8","volume":"78","author":"Ibanez","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ctarc.2026.101473_bib0023","article-title":"Duplex ultrasound for diagnosing symptomatic carotid stenosis in the extracranial segments","volume":"2022","author":"Cassola","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ctarc.2026.101473_bib0024","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0140-6736(18)32818-6","article-title":"Visualization of asymptomatic atherosclerotic disease for optimum cardiovascular prevention (VIPVIZA): a pragmatic, open-label, randomised controlled trial","volume":"393","author":"N\u00e4slund","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ctarc.2026.101473_bib0025","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1805971","article-title":"Coronary CT angiography and 5-year risk of myocardial infarction","volume":"379","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101473_bib0026","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1056\/NEJMoa2208681","article-title":"Five-year outcomes of the Danish cardiovascular screening (DANCAVAS) trial","volume":"387","author":"Lindholt","year":"2022","journal-title":"N. Engl. J. Med."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003825?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226003825?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:43:23Z","timestamp":1791488603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226003825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":26,"alternative-id":["S2468294226003825"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101473","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rethinking cardiovascular risk stratification in TKI-treated chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101473","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101473"}}